N/A N=32

Insulin Sensitivity in Patients With Atopic Dermatitis

Atopic Dermatitis/Eczema · Type 2 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT03003793 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2019

Primary outcome: Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Hyperinsulinemic euglycemic clamp (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University Hospital, Gentofte, Copenhagen
Primary completion: Sep 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls	9.8; 9.2	—

Summary

The incidence of atopic dermatitis and type 2 diabetes, respectively, has increased over many years. Novel research shows an association between the two conditions. While this relationship at least in theory can be explained by lifestyle factors, there is reason to believe that other pathophysiological mechanisms are involved. Hence, our hypothesis is that patients with atopic dermatitis are insulin resistant due to their chronic inflammatory state. Insulin resistance might play an unknown part in the increased frequency of type 2 diabetes among patients with atopic dermatitis. In the present project, the investigators aim to measure insulin sensitivity by means of the 'golden standard' hyperinsulinaemic euglycaemic clamp in patients suffering from atopic dermatitis compared to a healthy control group (matched case-control study). The project is a close collaboration between The Department of Dermatology and Allergy and Center for Diabetes Research at Gentofte Hospital.

Eligibility Criteria

Inclusion Criteria

Moderate to severe atopic dermatitis for at least 5 years
BMI < 30 kg/m2
HbA1c < 42 mmol/mol

Exclusion Criteria

Diabetes
Prediabetes
First-degree relatives with diabetes
Chronic inflammatory diseases other than atopic dermatitis and asthma
Pregnancy
Breast-feeding
Daily intake of medications that are known to influence the glucose metabolism are not allowed one month before the study (e.g. asthma medicines and hormonal contraception).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03003793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.